Aroa Biosurgery climbs as prelim annual results beat outlook

Aroa Biosurgery

30/04/2026 07:02

** Shares of Aroa Biosurgery ARX.AX rise as much as 21.8% to A$0.670, their biggest gain since late July 2020

** Soft-tissue regeneration products maker reports preliminary total revenue of NZ$101 million ($58.90 million)(constant currency) for FY26, exceeding guidance of NZ$92-100 million on constant currency basis

** Posts prelim normalised EBITDA of NZ$10-$11 million (constant currency),
exceeding FY26 guidance of NZ$ 5-8 million (constant currency)

** Around 774,000 shares change hands, nearly 5.8x 30-day average

** ARX down 15.5% YTD

($1 = 1.7147 New Zealand dollars)

(Reporting by Keshav Singh Chundawat in Bengaluru)

((Keshav.singhchundawat@thomsonreuters.com))